PBYI Puma Biotechnology Inc
Price (delayed)
$2.51
Market cap
$123.11M
P/E Ratio
13.21
Dividend/share
N/A
EPS
$0.19
Enterprise value
$154.55M
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights
Highlights
The P/E is 35% lower than the last 4 quarters average of 20.1
Puma Biotechnology's debt has decreased by 13% YoY and by 11% QoQ
Puma Biotechnology's equity has surged by 60% YoY but it has decreased by 4.9% QoQ
The net income has contracted by 43% from the previous quarter
PBYI's EPS is down by 42% since the previous quarter
Key stats
What are the main financial stats of PBYI
Market
Valuations
Earnings
Shares outstanding
49.05M
Market cap
$123.11M
Enterprise value
$154.55M
Price to earnings (P/E)
13.21
Price to book (P/B)
2.5
Price to sales (P/S)
0.55
EV/EBIT
6.58
EV/EBITDA
4.41
EV/Sales
0.71
Revenue
$219.14M
EBIT
$23.49M
EBITDA
$35.06M
Free cash flow
$33.25M
Per share
Balance sheet
Liquidity
EPS
$0.19
Free cash flow per share
$0.69
Book value per share
$1.01
Revenue per share
$4.54
TBVPS
$3.09
Total assets
$205M
Total liabilities
$156.49M
Debt
$98.59M
Equity
$48.51M
Working capital
$33.42M
Debt to equity
2.03
Current ratio
1.32
Quick ratio
1.2
Net debt/EBITDA
0.9
Margins
Efficiency
Dividend
EBITDA margin
16%
Gross margin
73.1%
Net margin
4%
Operating margin
8.6%
Return on assets
4.1%
Return on equity
18.2%
Return on invested capital
25.5%
Return on capital employed
23.3%
Return on sales
10.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PBYI stock price
How has the Puma Biotechnology stock price performed over time
Intraday
0.4%
1 week
9.13%
1 month
-27.67%
1 year
-25.3%
YTD
-42.03%
QTD
-23.01%
Financial performance
How have Puma Biotechnology's revenue and profit performed over time
Revenue
$219.14M
Gross profit
$160.15M
Operating income
$18.91M
Net income
$8.72M
Gross margin
73.1%
Net margin
4%
The net income has contracted by 43% from the previous quarter
Puma Biotechnology's net margin has decreased by 41% QoQ
The operating income has contracted by 27% from the previous quarter and by 13% YoY
The operating margin has contracted by 25% from the previous quarter and by 9% YoY
Growth
What is Puma Biotechnology's growth rate over time
Valuation
What is Puma Biotechnology stock price valuation
P/E
13.21
P/B
2.5
P/S
0.55
EV/EBIT
6.58
EV/EBITDA
4.41
EV/Sales
0.71
PBYI's EPS is down by 42% since the previous quarter
The P/E is 35% lower than the last 4 quarters average of 20.1
PBYI's P/B is 80% lower than its 5-year quarterly average of 12.3 and 34% lower than its last 4 quarters average of 3.8
Puma Biotechnology's equity has surged by 60% YoY but it has decreased by 4.9% QoQ
PBYI's P/S is 50% below its 5-year quarterly average of 1.1 and 31% below its last 4 quarters average of 0.8
The revenue has contracted by 4.8% YoY and by 3.3% from the previous quarter
Efficiency
How efficient is Puma Biotechnology business performance
PBYI's ROIC has soared by 180% YoY but it is down by 11% QoQ
PBYI's return on sales has surged by 123% year-on-year but it is down by 19% since the previous quarter
Puma Biotechnology's ROE has decreased by 49% from the previous quarter
The ROA has decreased by 43% QoQ
Dividends
What is PBYI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PBYI.
Financial health
How did Puma Biotechnology financials performed over time
The total assets is 31% more than the total liabilities
The company's current ratio fell by 33% YoY and by 10% QoQ
Puma Biotechnology's quick ratio has decreased by 31% YoY and by 10% from the previous quarter
Puma Biotechnology's debt is 103% higher than its equity
Puma Biotechnology's equity has surged by 60% YoY but it has decreased by 4.9% QoQ
Puma Biotechnology's debt to equity has decreased by 45% YoY and by 6% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.